|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||31.73 - 32.90|
|52-week range||31.51 - 68.12|
|PE ratio (TTM)||-7.09|
|Earnings date||7 Nov 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||55.44|
Mallinckrodt plc (MNK) announced that it will initiate a new phase IV study on H.P. Acthar Gel as a therapy option in patients with symptomatic sarcoidosis.
Mallinckrodt plc (MNK) entered into a licensing agreement with NeuroproteXeon for the development and commercialization of the latter's investigational, pharmaceutical-grade xenon gas for inhalation therapy.
Mallinkrodt was being investigated in connection with big price increases for its drug Achthar Gel, used to treat lupus and multiple sclerosis.
The iShares Nasdaq Biotechnology ETF (IBB) briefly fell more than 2.5 percent, tracking for its first negative day of 2017.
Mallinckrodt said it recently experienced temporary "production issues" with a third-party manufacturer supporting its immunotherapy platform, Therakos.
Mallinckrodt plunged nearly 10 percent Wednesday after Andrew Left claimed the firm's CEO has committed securities fraud.
Andrew Left said it was "completely outrageous" for the Senate to try to make Mylan "the next victim of public outcry over pharmaceutical pricing."